What BEGONIA Actually Changes in Clinical Practice

By
Published Updated Last reviewed
Clinical medical image for trials begonia: What BEGONIA Actually Changes in Clinical Practice

At a glance

| Trial Detail | Value | |---|---| | Name | BEGONIA | | N | 949 premenopausal women | | Intervention | Flibanserin 100 mg nightly | | Comparator | Placebo | | Duration | 24 weeks | | Primary Endpoint | Change in number of satisfying sexual events (SSEs) and sexual desire score (eDiary) | | Key Result | Statistically significant improvement in SSEs (~0.8 additional events/month over placebo) and desire scores |

The Trial That Got Addyi Over the Line

BEGONIA was one of three key Phase III trials (alongside VIOLET and DAISY) that formed the basis for flibanserin's FDA approval in August 2015. Sprout Pharmaceuticals had already been rejected twice by the FDA advisory committee before this dataset, combined with the others, tipped the risk-benefit assessment narrowly in favor of approval.

The trial enrolled 949 premenopausal women meeting DSM-IV-TR criteria for generalized acquired HSDD. Participants were randomized 1:1 to flibanserin 100 mg or placebo taken at bedtime for 24 weeks. The bedtime dosing was not arbitrary. Earlier dose-finding work revealed that daytime administration caused unacceptable somnolence and hypotension rates. This constraint is worth remembering because it later became central to the REMS program and remains a practical barrier in clinical use.

What separates BEGONIA from a typical efficacy readout is the co-primary endpoint structure. The FDA required improvement on both a patient-reported desire measure (eDiary) and a behavioral outcome (SSEs). This dual requirement raised the bar and, depending on your perspective, either validated the drug's real-world relevance or set up a situation where modest numbers on both endpoints could be packaged as a win.

Methodology: What the Abstract Doesn't Tell You

The BEGONIA investigators used an electronic diary system where participants logged desire, arousal, and sexual activity daily. This is stronger than monthly recall questionnaires, which are vulnerable to recency bias. But the eDiary approach introduces its own issue: measurement reactivity. Women who log their sexual experiences nightly may behave differently than they would otherwise. Both arms were subject to this, so it doesn't invalidate the comparison, but it complicates translation to real-world outcomes where no one keeps a nightly log.

Inclusion criteria required a baseline of 2 to 6 SSEs per month and a Female Sexual Function Index (FSFI) desire domain score <5. Women with depression, anxiety on medication, or any substance use disorder were excluded. This is a critical point for clinical practice. The population studied was psychiatrically clean, medically healthy, in stable relationships, and motivated enough to complete 24 weeks of nightly diary entries.

The HealthRX Clinical Translation Framework for BEGONIA

When evaluating whether BEGONIA data applies to a specific patient, we use three filters:

  1. Psychiatric comorbidity filter. If the patient has active depression, anxiety requiring pharmacotherapy, or takes SSRIs/SNRIs (which independently suppress desire), BEGONIA data do not directly apply. The trial excluded these patients, and the mechanism of flibanserin (5-HT1A agonism, 5-HT2A antagonism) could interact unpredictably with serotonergic medications.

  2. Relationship context filter. BEGONIA required participants to be in stable, communicative partnerships. Desire discrepancy in the context of relationship distress, unresolved conflict, or partner sexual dysfunction was not studied. Prescribing flibanserin without addressing these factors is prescribing into a data vacuum.

  3. Expectation calibration filter. The placebo arm improved by roughly 0.5 to 1.0 SSEs per month. The drug arm added approximately 0.8 events beyond that. Telling a patient "this medication may give you about one additional satisfying sexual encounter per month compared to no treatment" is honest. Telling her "this will restore your desire" is not supported by the data.

Results: The Numbers That Matter

The primary efficacy results showed:

| Outcome | Flibanserin | Placebo | Difference | P-value | |---|---|---|---|---| | Change in SSEs/month | +1.6 | +0.8 | +0.8 | <0.01 | | Change in desire score (eDiary) | +4.2 | +2.7 | +1.5 | <0.01 | | FSFI desire domain improvement | +0.7 | +0.4 | +0.3 | <0.05 | | Distress score reduction (FSDS-R Item 13) | -0.7 | -0.4 | -0.3 | <0.01 |

Statistical significance was achieved on all co-primary and key secondary endpoints. The clinical significance is where disagreement starts.

An increase of 0.8 SSEs per month over placebo translates to roughly one additional satisfying sexual event every 5 weeks attributable to the drug. The desire score improvement, while statistically significant, represented less than a 10% shift on the scale used. The distress reduction was real but small.

The responder analysis is more encouraging. Approximately 46% of women on flibanserin reported "much improved" or "very much improved" on the Patient Global Impression of Improvement, compared to 30% on placebo. This 16-percentage-point spread suggests a subgroup of women who genuinely benefit, even if the average treatment effect looks modest.

Safety: The Alcohol Interaction That Shaped Everything

Adverse events in BEGONIA were consistent with the broader flibanserin program:

| Adverse Event | Flibanserin (%) | Placebo (%) | |---|---|---| | Dizziness | 11.4 | 2.3 | | Somnolence | 11.2 | 3.0 | | Nausea | 10.4 | 3.6 | | Fatigue | 6.3 | 2.5 | | Insomnia | 4.9 | 2.1 |

Dizziness and somnolence are dose-limiting and were the primary reason bedtime dosing became mandatory. The dropout rate due to adverse events was 9.6% on flibanserin versus 3.7% on placebo.

The alcohol interaction was not fully characterized in BEGONIA itself but emerged from a dedicated pharmacokinetic study conducted during the approval process. Combining flibanserin with alcohol produced severe hypotension and syncope in some participants. This led to the unprecedented REMS requirement: prescribers must be certified, patients must be counseled about alcohol abstinence, and pharmacies must be specially enrolled. The REMS has been the single biggest brake on real-world uptake.

What Changed in Guidelines After BEGONIA

The International Society for the Study of Women's Sexual Health (ISSWSH) updated its HSDD process of care algorithm to include flibanserin as a pharmacologic option for premenopausal HSDD after the key trials were published. The algorithm places flibanserin after biopsychosocial assessment and sex therapy or counseling have been considered.

The American College of Obstetricians and Gynecologists (ACOG) acknowledged FDA approval but stopped short of a strong recommendation, noting that clinicians should discuss "limited efficacy data and potential adverse effects" with patients. This lukewarm endorsement reflects the gap between statistical significance and clinical enthusiasm.

In practice, prescribing patterns shifted less than the approval would suggest. IMS Health data from 2016 showed fewer than 4,000 prescriptions per month in the first year post-approval. By comparison, sildenafil had over 300,000 prescriptions in its first three months. Several factors explain this:

  • The REMS certification created friction for primary care physicians and gynecologists.
  • Insurance coverage was inconsistent, with many plans requiring prior authorization or denying coverage entirely.
  • The modest effect sizes made clinicians cautious about setting patient expectations.
  • The alcohol restriction was perceived as burdensome in a population that did not view moderate drinking as a medical risk.

Patients Who Differ From the Trial Population

BEGONIA's exclusion criteria created a population that does not represent the typical woman presenting with low desire in a primary care or gynecology office.

SSRI users. Perhaps the most common real-world scenario. A premenopausal woman on sertraline or escitalopram for anxiety or depression reports loss of desire. BEGONIA excluded her. There is no randomized evidence for flibanserin in this population, and the serotonergic mechanism overlap raises theoretical safety concerns. A 2018 post-hoc analysis from the broader program suggested no pharmacokinetic interaction, but efficacy in this subgroup remains unproven.

Postmenopausal women. A separate trial (SNOWDROP) studied flibanserin in postmenopausal women and showed similar modest effects. The FDA approval, however, is limited to premenopausal women. Off-label postmenopausal prescribing occurs but lacks the regulatory backing that BEGONIA helped establish for the approved indication.

Women with situational (not generalized) HSDD. BEGONIA required generalized acquired HSDD, meaning desire was reduced across all situations and partners. Women whose low desire is partner-specific or context-dependent were not studied. There is no mechanistic reason to expect a centrally acting serotonergic agent to resolve relationship-specific desire concerns.

Women over 50 who are still premenopausal. The mean age in BEGONIA was approximately 36. While the indication covers all premenopausal women, the applicability to late-perimenopausal patients (who may have fluctuating hormones contributing to desire changes) is less clear.

The Bigger Picture: Bremelanotide and Combination Approaches

BEGONIA did not exist in isolation. Bremelanotide (Vyleesi), a melanocortin receptor agonist approved in 2019, offered an alternative mechanism. The RECONNECT trials showed a similar magnitude of benefit (roughly 0.5 additional SSEs per month over placebo) with an on-demand dosing model that eliminated the daily commitment and alcohol restriction.

The availability of two approved agents with different mechanisms has raised the question of combination therapy. No randomized data exist for flibanserin plus bremelanotide together. Some clinicians have explored sequential trials (3 to 6 months of one agent, switching to the other if response is inadequate), but this remains empirical rather than evidence-based.

Limitations the Authors Acknowledged

The BEGONIA investigators were transparent about several weaknesses. The 24-week duration, while standard for regulatory purposes, does not answer whether benefits persist at 12 or 24 months. An open-label extension suggested sustained response, but without a placebo comparator, regression to the mean and placebo carryover cannot be excluded.

The generalizability concern was noted explicitly. The trial population was predominantly white (82%), partnered, and free of psychiatric comorbidity. The FDA label reflects these limitations in its clinical studies section.

The endpoint of SSEs has itself been criticized. Counting sexual events reduces a complex experience to a frequency measure. A woman might have fewer encounters but find them more satisfying, or more encounters driven by obligation rather than genuine desire. The eDiary desire score partially addresses this, but it remains a single-item self-report.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Derogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the BEGONIA trial. J Sex Med. 2012;9(7):1807-1815. PubMed
  2. U.S. Food and Drug Administration. Addyi (flibanserin) prescribing information. 2015. FDA Label
  3. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114-128. PubMed
  4. Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633-640. PubMed
  5. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PubMed